文章摘要
沈 昊,谢利军.莫西沙星与左氧氟沙星治疗耐多药结核病有效性及安全性Meta分析[J].南京医科大学学报,2014,(12):1800~1807
莫西沙星与左氧氟沙星治疗耐多药结核病有效性及安全性Meta分析
Efficacy and safety of moxifloxacin and levofloxacin in the treatment of multidrug resistance tuberculosis:a meta-analysis
投稿时间:2014-07-21  
DOI:10.7655/NYDXBNS20141252
中文关键词: 莫西沙星  左氧氟沙星  耐多药结核  Meta分析
英文关键词: moxifloxacin  levofloxacin  multidrug resistance tuberculosis  Meta-analysis
基金项目:科技部科技重大专项“重大新药创制” (2011ZX09302-003-02);江苏省科技重大专项(BM2011017)
作者单位
沈 昊 南京医科大学第一附属医院国家药物临床试验机构,江苏 南京 210029 
谢利军 南京医科大学第一附属医院国家药物临床试验机构,江苏 南京 210030 
摘要点击次数: 508
全文下载次数: 373
中文摘要:
      目的:评价国内莫西沙星与左氧氟沙星治疗耐多药结核病的疗效及安全性?方法:计算机检索中国生物医学文献数据库?中国期刊全文数据库?万方数据库及维普中文科技期刊全文数据库,收集2000年1月~2014年6月莫西沙星与左氧氟沙星治疗耐多药结核病的随机对照试验(RCT)文献,对纳入研究进行方法学质量评价,并采用RevMan 5.3.0软件进行Meta分析?结果:共纳入36个RCT?Meta分析结果显示,莫西沙星组与左氧氟沙星组相比,莫西沙星可提高服药后3个月痰菌转阴率(OR=2.25,95%CI:1.87~2.70)?疗程结束时痰菌转阴率(OR=3.70,95%CI:2.97~4.62)?病灶吸收率(OR=2.45,95%CI:1.90~3.17)?空洞闭合率(OR=1.82,95%CI:1.45~2.29)以及临床总有效率(OR=5.08,95%CI:3.58~7.22)?两组不良反应发生率差异无统计学意义(P=0.14)?结论:目前国内证据表明,莫西沙星可有效治疗耐多药结核病,其疗效优于左氧氟沙星,不良反应发生率与其相当?
英文摘要:
      Objective:To evaluate the efficacy and safety of moxifloxacin as well as levofloxacin in the treatment of multidrug resistance tuberculosis (MDR-TB) in China. Methods:Databases included the CB1Mdisc,CNKI,wangfang data,and VIP from Jan,2000 to Jun,2014 were retrospectively searched to collect randomized controlled trials (RCTs) of moxifloxacin and levofloxacin for MDR-TB. The methodological quality of included studies was evaluated,and data analyses were performed with The Cochrane Collaboration’s software RevMan 5.3.0. Results:A total of 36 RCTs were included. The results showed that,compared with the levofloxacin group,moxifloxacin increased the sputum negative conversion rate after 3-month taking(OR=2.25,95%CI:1.87~2.40)and at the end of the treatment period(OR=3.70,95%CI:2.97~4.62). Moxifloxacin was more effective in focus absorption(OR=2.45,95%CI:1.90~3.17),cavity closure(OR=1.82,95%CI:1.45~2.29)and clinical curative effect(OR=5.08,95%CI:3.58~7.22). However,there was no statistical difference in incidence of adverse reaction (P=0.14). Conclusion:According to the domestic evidence,moxifloxacin is more effective for MDR-TB than levofloxacin. Its adverse reaction rate is equivalent to levofloxacin.
查看全文   查看/发表评论  下载PDF阅读器
关闭